Analyzing...
Loading company...
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 18,468 full-time employees. The company went IPO on 2023-05-09. The firm is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹14,278 Cr revenue.
COGS 28.4%, employees 22.3%.
“going forward next year, double digit growth, good double digit growth will be there.”
“revenue increased by 11.”
“% year on year to rupees 10,835 crore rupees with adjusted EBITDA margin of 24.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.7%▲ | 10.3% |
| ROCE | 13.7%▲ | 13.7% |
| Net Margin | 13.1%▲ | 7.6% |
| EBITDA Margin | 26.3%▲ | 15.4% |
| Debt To Equity | 0.39x▲ | 0.15x |
| Rev Growth 3yr | 18.1%▲ | 10.0% |
| EPS Growth 3yr | 13.1%▼ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹14,738 Cr +20.7% | ₹12,207 Cr +18.1% | ₹10,335 Cr +18.1% | ₹8,749 Cr |
| Other Income | ₹324 Cr -39.7% | ₹537 Cr +91.1% | ₹281 Cr +118.5% | ₹129 Cr |
| Total Income | ₹15,062 Cr +18.2% | ₹12,744 Cr +20.1% | ₹10,616 Cr +19.6% | ₹8,878 Cr |
| COGS | ₹4,097 Cr +17.4% | ₹3,489 Cr +8.7% | ₹3,210 Cr +10.2% | ₹2,914 Cr |
| ₹12,383 Cr +20.9% | ₹10,240 Cr +24.4% | ₹8,231 Cr +14.0% | ₹7,219 Cr | |
| Profit Before Tax | ₹2,549 Cr +1.8% | ₹2,504 Cr +5.0% | ₹2,384 Cr +43.7% | ₹1,659 Cr |
| Exceptional Items | (₹130 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹494 Cr -3.1% | ₹510 Cr +11.4% | ₹458 Cr +26.6% | ₹362 Cr | |
| Net Profit | ₹2,068 Cr +2.8% | ₹2,011 Cr +3.6% | ₹1,942 Cr +48.3% | ₹1,310 Cr |
| Profit (Owners) | ₹2,049 Cr +2.9% | ₹1,991 Cr +4.1% | ₹1,913 Cr +49.2% | ₹1,282 Cr |
| Minority Interest | ₹19 Cr -6.4% | ₹20 Cr -30.2% | ₹29 Cr +3.8% | ₹28 Cr |
| Other Comprehensive Income | ₹37 Cr ↑ Recovery | (₹8 Cr) -3.4% | (₹8 Cr) -324.9% | (₹2 Cr) |
| EPS | ₹49.62 | ₹48.26 | ₹47.75 | ₹32.00 |
| Diluted Shares | ₹41 Cr | ₹41 Cr | ₹40 Cr | ₹40 Cr |
| Profit Or Loss Of Associates | ₹12 Cr +1.8% | ₹12 Cr -19.5% | ₹15 Cr +22.5% | ₹12 Cr |
| Profit Loss From Discontinued Operations After Tax | ₹0.00 Cr -100.0% | ₹5 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Mankind Pharma Limited has informed the Exchange about Link of Recording
Please find attached certificate under Regulation 54 of the SEBI (LODR) Regulations, 2015
Mankind Pharma Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "Press Release on Financial Results for Q1FY27".
Mankind Pharma Limited has informed the Exchange about Investor Presentation
Mankind Pharma Limited has informed the Exchange about Giving guarantees/indemnity/ becoming a surety for third party
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Final update on Stake Sale of Broadway Hospitality Services Private Limited
Mankind Pharma Limited has informed the Exchange about Schedule of meet
Mankind Pharma Limited has informed the Exchange about Acquisition
Mankind Pharma Limited has informed the Exchange about Diversification/Disinvestment
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 11, 2026.
Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication